Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trials

Nintedanib is a tyrosine kinase inhibitor used to treat idiopathic pulmonary fibrosis (IPF). We investigated the cardiovascular safety of nintedanib using pooled data from the TOMORROW and INPULSIS trials. Cardiovascular events were assessed post hoc in patients with a history of atherosclerotic car...

Descripción completa

Detalles Bibliográficos
Autores principales: Noth, Imre, Wijsenbeek, Marlies, Kolb, Martin, Bonella, Francesco, Moros, Lizette, Wachtlin, Daniel, Corte, Tamera J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6766682/
https://www.ncbi.nlm.nih.gov/pubmed/31285303
http://dx.doi.org/10.1183/13993003.01797-2018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6766682/
https://www.ncbi.nlm.nih.gov/pubmed/31285303
http://dx.doi.org/10.1183/13993003.01797-2018

Ejemplares similares